4//SEC Filing
RXi Pharmaceuticals Corp 4
Accession 0001209191-17-039027
$PHIOCIK 0001533040operating
Filed
Jun 8, 8:00 PM ET
Accepted
Jun 9, 9:55 PM ET
Size
7.1 KB
Accession
0001209191-17-039027
Insider Transaction Report
Form 4
Eliseev Alexey
Chief Business Officer
Transactions
- Conversion
Common stock, $0.0001 par value
2017-06-09+332,499→ 1,150,312 total - Conversion
Series C Convertible Preferred Stock, $0.0001 par value
2017-06-09−332,499→ 0 total→ Common stock (332,499 underlying)
Footnotes (1)
- [F1]The Series C Convertible Preferred Stock automatically converted into common stock upon approval by the Company's stockholders in accordance with the stockholder approval requirements of Nasdaq Marketplace Rule 5635 without payment of consideration. The Series C Convertible Preferred Stock have no expiration.
Documents
Issuer
RXi Pharmaceuticals Corp
CIK 0001533040
Entity typeoperating
IncorporatedDE
Related Parties
1- filerCIK 0001533040
Filing Metadata
- Form type
- 4
- Filed
- Jun 8, 8:00 PM ET
- Accepted
- Jun 9, 9:55 PM ET
- Size
- 7.1 KB